secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xeris Biopharma Holdings, Inc. (XERS)
CIK:        0001867096
Form:       8-K
Filed at:   2023-03-08T23:59:59+00:00
Accession:  0001867096-23-000027
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xeris reports Q4 product revenue $32.5M (+52% YoY); guides 2023 revenue $135-165M, cash flow breakeven Q4 2023
--------------------------------------------------------------------------------

- Q4 net product revenue $32.5M, up 52% YoY; full-year 2022 net product revenue $109.3M, up 38% pro forma.
- Q4 net loss $12.9M ($0.10/sh); full-year net loss $94.7M ($0.70/sh). Cash at Dec 31, 2022: $122.0M.
- 2023 guidance: total revenue $135M-$165M, cash utilization $57-77M, year-end cash $45-65M; targets cash flow breakeven in Q4 2023.
- Announced research collaboration with Horizon Therapeutics for XeriJect formulation of TEPEZZA; $2.75M upfront payment.
- Gvoke NRx market share >28% at Feb 2023; Recorlev granted FDA orphan-drug exclusivity.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1867096/000186709623000027/0001867096-23-000027-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1867096/000186709623000027/xers-20230308.htm
  HTML page:      https://secwatch.observer/filing/0001867096-23-000027

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer